Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

94.7%

+8.2% vs industry average

Late-Stage Pipeline

30%

7 trials in Phase 3/4

Results Transparency

0%

0 of 18 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
7(53.8%)
Phase 2
5(38.5%)
Phase 1
1(7.7%)
13Total
Phase 3(7)
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT05928286Completed

Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

Role: lead

NCT05935787Phase 3Completed

Cytoflavin in the Complex Rehabilitation of Stroke Patients

Role: lead

NCT05789797Completed

Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy

Role: lead

NCT07066540Recruiting

Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

Role: lead

NCT06955416Phase 2Recruiting

REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis

Role: lead

NCT06183229Phase 3Completed

Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

Role: lead

NCT06183242Phase 2Completed

Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis

Role: lead

NCT04631484Phase 3Completed

International Trial of Efficacy of Cytoflavin in Head Trauma

Role: lead

NCT06514976Recruiting

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Role: lead

NCT05715723Completed

Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

Role: lead

NCT06735898Recruiting

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome

Role: lead

NCT05172180Completed

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

Role: lead

NCT06286254Completed

Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection

Role: lead

NCT04194229Completed

Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke Survivors

Role: lead

NCT05297851Completed

Cytoflavin in Combination With Reperfusion in Stroke Patients

Role: lead

NCT03849664Phase 3Completed

Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery

Role: lead

NCT04649203Phase 3Completed

Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy

Role: lead

NCT05147051Phase 2Completed

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Role: lead

NCT03028285Phase 1Completed

Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers

Role: lead

NCT03418935Phase 3Completed

Remaxol® in Mechanical Jaundice of Non-malignant Origin

Role: lead